{"name":"IVIEW Therapeutics Inc.","slug":"iview-therapeutics-inc","ticker":"","exchange":"","domain":"iview.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1978-01-01","label":"NATACYN® first approved","drug":"NATACYN®","drugSlug":"natacyn","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"IVIEW-1201","genericName":"IVIEW-1201","slug":"iview-1201","indication":"Other","status":"phase_2"},{"name":"IVW-1001 Ophthalmic Eyelid Wipe 0.2%","genericName":"IVW-1001 Ophthalmic Eyelid Wipe 0.2%","slug":"ivw-1001-ophthalmic-eyelid-wipe-0-2","indication":"Other","status":"phase_2"},{"name":"NATACYN®","genericName":"NATACYN®","slug":"natacyn","indication":"Fungal Blepharitis","status":"marketed"}]}],"pipeline":[{"name":"IVIEW-1201","genericName":"IVIEW-1201","slug":"iview-1201","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IVW-1001 Ophthalmic Eyelid Wipe 0.2%","genericName":"IVW-1001 Ophthalmic Eyelid Wipe 0.2%","slug":"ivw-1001-ophthalmic-eyelid-wipe-0-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NATACYN®","genericName":"NATACYN®","slug":"natacyn","phase":"marketed","mechanism":"Small molecule","indications":["Fungal Blepharitis","Fungal conjunctivitis","Fungal keratitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQVEsxc09FbngtV09IMHlVcmlsZDhWTjh2Q0IzUWhXT3dxRVN4N3VxS3RuOXlSZkNfZ3p5SWFfZmtZd0ZmZVRFWERVMm1YR2pIYllsLVpuS01HMTVEMXY1N0NlQVR6WGxfMDIydG44VmNRZzhHSWQ0ZGN3OThFTkxxM3NLMThWdGxGRWpkbUxQbw?oc=5","date":"2026-03-27","type":"pipeline","source":"openPR.com","summary":"Chlamydia Infections Pipeline 2026: Therapies Under - openPR.com","headline":"Chlamydia Infections Pipeline 2026: Therapies Under","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNUzN1MEE0NTlVbzNzYkRsc2ZNVXFjX002SEpKcW91U3gzNGRrRVdyakd2bjBVbWlUSjVrTkZPekxuOERHeWt4dEwxNVR4YzZkamZiY21td2N3b2RNdWNNeVNNcjV3ZmliWlJ1ZmNwMTBudmktaUI0RkJzekpxa3QwY2t0all1Si1LZ2FNN21ZcTZuNFBwZWhfSld0cjA4MEVMdktmQ1FTM3ZrM2V5cFVMbDdwVTFQY01yWjZkX04yNnlRVTVxbXlKLTd3MHNXc2habEp0TTNYcXpuaG42SkJMcmVtaHNxUmt3RVdQbTZDNGQwUjR6LWVWN0NvbEpvenlkWk5ZWXp3?oc=5","date":"2026-03-12","type":"trial","source":"StreetInsider","summary":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - StreetInsider","headline":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9vaG8tMVNIcEVoY1NKQlBhQ1NnSnh3elNwMTZydGZ5aC1ScDgwNWRIeUIyWVlnVWVkamdXWW9mUXg0aTNRVmJvMmdIQ2xuMHNLaE1DdzQ4M05lODBUa0xEeldzNWE?oc=5","date":"2025-03-17","type":"pipeline","source":"NJBIZ","summary":"A – L | NJBIZ In the Lead 2025: Startups - NJBIZ","headline":"A – L | NJBIZ In the Lead 2025: Startups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"PR Newswire","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - PR Newswire","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPOUxzZmtLU2pZQjh6d0RtZXRKczJvSGNBcHVhSkFNYTh1X29nLUJoS3dWREZsbG12S1NaNFdVcWdVNlNZX3ZzeTc1UDBpNHp3alQ2VFEySzBSRVlTMnRMS1U4Z0wtTVFKOF8zaVBlT21MbmxFT3hpcU1vWG95VFF6X0NaVUJ1bTZjNF9ZZDVQU3RQNXJvTEQtMFFYOTAyc3RjTjcyRHhrVDRZMnA3LUpJQnRpU2EyY0N4cTFZT0VVaWZxNmg3amdVZ2V3MEVtR1MzMFNOYmhoT1FQUDBYanF3TjhKaDYxQU9SVzlqdksxTmE5RFFm?oc=5","date":"2024-09-18","type":"trial","source":"Ophthalmology Times","summary":"iView Therapeutics completes enrollment in phase 1/2 trial for ophthalmic eyelid wipe for the treatment of dry eye disease - Ophthalmology Times","headline":"iView Therapeutics completes enrollment in phase 1/2 trial for ophthalmic eyelid wipe for the treatment of dry eye disea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQdDBCUzI0UHNybzhPQkZ0UW50dVVTSUNyV2F1Qmk0NjhsX0xnUnRJcV9naGgxaVlMRGdOSkx6WmdGUGIydTYyTWlLNXduZjNvMDRYeHJxOVBZY01wSXBEQm14SjN6c0ZTWjRwX29SUGI2ck9BaXh5RFhTdmtDQmk1RkhFTk9JSmxaM1BnWjVBZTJJY0UtNTlKWG95dDhwRG9kZWxfRmo5VHp6bHU3U19kUE1OenJvV2FOcjhrdVpkRnY0S3pJ?oc=5","date":"2024-03-12","type":"regulatory","source":"Ophthalmology Times","summary":"FDA clears iView Therapeutics IND application to start trial of TRPM8 agonist, IVW-1001 - Ophthalmology Times","headline":"FDA clears iView Therapeutics IND application to start trial of TRPM8 agonist, IVW-1001","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}